Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of SOM230 in Treating Non-Functioning Pituitary Adenomas
2005-004413-15Phase 2Terminated
- Sponsor
- Cedars-Sinai
- Start
- Nov 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in pituitary adenoma, sponsored by Cedars-Sinai. Primary endpoint: Change in tumor size by MRI. Started Nov 2006; status: terminated.
02
Drugs
pasireotide LAR
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on 2005-004413-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004413-15.